{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:24:42Z","timestamp":1793247882367,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["270650915\/GRK2158"],"award-info":[{"award-number":["270650915\/GRK2158"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbamcr.2025.120018","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:38:54Z","timestamp":1751431134000},"page":"120018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome acquired cisplatin resistance of tumor cells"],"prefix":"10.1016","volume":"1872","author":[{"given":"Marlena","family":"Sekeres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lengle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Abbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias Ulrich","family":"Kassack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbamcr.2025.120018_bb0005","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0015","article-title":"Targeting the DNA damage response for cancer therapy","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0020","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1021\/cr900047g","article-title":"Targeting the DNA damage response in cancer","volume":"109","author":"Ljungman","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ijc.35164","article-title":"Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse","volume":"156","author":"Mann","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0035","first-page":"10017","article-title":"The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair","volume":"44","author":"Roos","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113698","article-title":"Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia","volume":"173","author":"Lernoux","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0060","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2174\/0929867322666150416094720","article-title":"Histone deacetylase inhibitors: potent anti-leukemic agents","volume":"22","author":"Bian","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/13543776.2014.877446","article-title":"Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011\u22122013)","volume":"24","author":"Valente","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0070","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.3390\/ph3082674","article-title":"Overview of histone deacetylase inhibitors in haematological malignancies","volume":"3","author":"Bishton","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0075","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tips.2017.11.008","article-title":"Combination therapies targeting HDAC and IKK in solid tumors","volume":"39","author":"Vancurova","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.bbamcr.2025.120018_bb0090","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10637-010-9596-y","article-title":"Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect","volume":"28","author":"Dickinson","year":"2010","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0095","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/cas.12717","article-title":"Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage","volume":"106","author":"Fukuda","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0100","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.tips.2017.05.009","article-title":"Interstrand crosslink repair as a target for HDAC inhibition","volume":"38","author":"Nikolova","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0105","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nsmb.1899","article-title":"Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining","volume":"17","author":"Miller","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03096-0","article-title":"HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130","volume":"9","author":"Goder","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0115","doi-asserted-by":"crossref","first-page":"11260","DOI":"10.1021\/acs.jmedchem.9b01489","article-title":"Synthesis of peptoid-based class I selective histone deacetylase inhibitors with chemosensitizing properties","volume":"62","author":"Krieger","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.09.018","article-title":"Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer","volume":"329","author":"Diyabalanage","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0125","doi-asserted-by":"crossref","first-page":"17796","DOI":"10.1021\/acs.jmedchem.4c01817","article-title":"Hydrazide-based class I selective HDAC inhibitors completely reverse chemoresistance synergistically in platinum-resistant solid cancer cells","volume":"67","author":"Kraft","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0130","doi-asserted-by":"crossref","first-page":"41320","DOI":"10.18632\/oncotarget.9321","article-title":"Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells","volume":"7","author":"Hohn","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0135","article-title":"Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors","volume":"211","author":"Avelar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0140","doi-asserted-by":"crossref","first-page":"21223","DOI":"10.1021\/acs.jmedchem.4c02024","article-title":"Deciphering the therapeutic potential of novel pentyloxyamide-based class I, IIb HDAC inhibitors against therapy-resistant leukemia","volume":"67","author":"Fischer","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0145","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1021\/acs.jmedchem.6b01538","article-title":"Alkoxyurea-based histone deacetylase inhibitors increase cisplatin potency in chemoresistant cancer cell lines","volume":"60","author":"Stenzel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0091-679X(04)75014-1","article-title":"Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation","volume":"75","author":"Olive","year":"2004","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0160","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0165","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2741\/3652","article-title":"Replication protein A: directing traffic at the intersection of replication and repair","volume":"15","author":"Oakley","year":"2010","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nprot.2006.5","article-title":"The comet assay: a method to measure DNA damage in individual cells","volume":"1","author":"Olive","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0175","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, recognition, and processing of cisplatin-DNA adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkl051","article-title":"Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei","volume":"34","author":"Liedert","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.leukres.2016.03.007","article-title":"Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin","volume":"45","author":"Robert","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134747","article-title":"In vitro assessment of the genotoxic hazard of novel hydroxamic acid- and benzamide-type Histone Deacetylase Inhibitors (HDACi)","volume":"21","author":"Friedrich","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0195","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0200","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1002\/1878-0261.13042","article-title":"Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer","volume":"15","author":"Chambers","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0205","first-page":"8554","article-title":"Replication protein A2 phosphorylation after DNA damage by the coordinated action of ataxia telangiectasia-mutated and DNA-dependent protein kinase","volume":"61","author":"Wang","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0210","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkn550","article-title":"Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin","volume":"36","author":"Kinner","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0215","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Marechal","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0220","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.molcel.2007.11.015","article-title":"The DNA damage response: ten years after","volume":"28","author":"Harper","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0225","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0959-437X(00)00159-3","article-title":"ATM and ATR: networking cellular responses to DNA damage","volume":"11","author":"Shiloh","year":"2001","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0230","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0235","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/1541-7786.MCR-11-0134","article-title":"The ATM substrate KAP1 controls DNA repair in heterochromatin: regulation by HP1 proteins and serine 473\/824 phosphorylation","volume":"10","author":"White","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0240","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1158\/1535-7163.MCT-15-0374","article-title":"Differences in expression of key DNA damage repair genes after epigenetic-induced BRCAness dictate synthetic lethality with PARP1 inhibition","volume":"14","author":"Wiegmans","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0245","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.18632\/oncotarget.14062","article-title":"Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0250","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1093\/nar\/gkae426","article-title":"The p21CIP1-CDK4-DREAM axis is a master regulator of genotoxic stress-induced cellular senescence","volume":"52","author":"Schmidt","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0255","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1046\/j.1432-1327.2001.02228.x","article-title":"Regulation of cellular senescence by p53","volume":"268","author":"Itahana","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0260","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2015-03-632984","article-title":"Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies","volume":"126","author":"Matthews","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0265","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jare.2023.07.005","article-title":"Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells","volume":"60","author":"Fischer","year":"2024","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0270","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0275","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41589-022-01015-5","article-title":"Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target","volume":"18","author":"Lechner","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0280","first-page":"809","article-title":"Reply to: ricolinostat is not a highly selective HDAC6 inhibitor","volume":"4","author":"Silva","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0285","first-page":"807","article-title":"Ricolinostat is not a highly selective HDAC6 inhibitor","volume":"4","author":"M\u00e9dard","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0290","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-2898","article-title":"Inhibition of HDAC6 as a novel targeted therapy in breast cancer","volume":"78","author":"Zeleke","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0295","first-page":"257","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0300","first-page":"257","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0305","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1200\/JCO.21.00944","article-title":"E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group","volume":"39","author":"Connolly","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0310","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00277-023-05552-4","article-title":"A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes\/neoplasms or acute myeloid leukemia refractory to hypomethylating agents","volume":"103","author":"Bewersdorf","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0315","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/0008-5472.CAN-03-2630","article-title":"Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275","volume":"64","author":"Camphausen","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0320","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-04751-7","article-title":"Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression","volume":"13","author":"Hanisch","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116743","article-title":"Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer","volume":"175","author":"Giri","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16193374","article-title":"Triple combination of entinostat, a bromodomain inhibitor, and cisplatin is a promising treatment option for bladder cancer","volume":"16","author":"Bollmann","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0335","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138560","article-title":"Entinostat induces antitumor immune responses through immune editing of tumor neoantigens","volume":"131","author":"Truong","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/biom7010019","article-title":"Common chemical inductors of replication stress: focus on cell-based studies","volume":"7","author":"Vesela","year":"2017","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0345","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1172\/JCI60806","article-title":"HDAC3 is essential for DNA replication in hematopoietic progenitor cells","volume":"123","author":"Summers","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0350","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0092-8674(00)80521-8","article-title":"Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain","volume":"90","author":"Gu","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0355","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.molcel.2006.11.021","article-title":"Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis","volume":"24","author":"Tang","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0360","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ncb1743","article-title":"Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR","volume":"10","author":"Winter","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201900127","article-title":"Cell fate regulation upon DNA damage: p53 serine 46 kinases pave the cell death road","volume":"41","author":"Liebl","year":"2019","journal-title":"Bioessays"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0370","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1038\/onc.2010.183","article-title":"Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells","volume":"29","author":"Puca","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0375","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1002\/1878-0261.13060","article-title":"Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells","volume":"15","author":"Marx","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0380","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s10565-022-09731-3","article-title":"The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil","volume":"39","author":"Kiweler","year":"2023","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0385","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc1435","article-title":"Transcription - guarding the genome by sensing DNA damage","volume":"4","author":"Ljungman","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0390","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.trecan.2021.09.002","article-title":"Chromosomal instability and aneuploidy as causes of cancer drug resistance","volume":"8","author":"Lukow","year":"2022","journal-title":"Trends Can."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0395","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fgene.2020.00228","article-title":"Drug targeting of genomic instability in multiple myeloma","volume":"11","author":"Beksac","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0400","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.canlet.2008.06.005","article-title":"Histone deacetylase inhibitors and genomic instability","volume":"274","author":"Eot-Houllier","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.07.052","article-title":"Novel alpha,beta-unsaturated hydroxamic acid derivatives overcome cisplatin resistance","volume":"27","author":"Pflieger","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0410","article-title":"Priming with HDAC inhibitors sensitizes ovarian cancer cells to treatment with cisplatin and HSP90 inhibitors","volume":"21","author":"Moita","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0415","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13148-018-0531-y","article-title":"Effects of novel HDAC inhibitors on urothelial carcinoma cells","volume":"10","author":"Kaletsch","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0420","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18342","article-title":"New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma","volume":"28","author":"Meneceur","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0425","doi-asserted-by":"crossref","first-page":"1705731","DOI":"10.1080\/23723556.2019.1705731","article-title":"Histone deacetylases facilitate the accurate repair of broken forks","volume":"7","author":"Gomez-Gonzalez","year":"2020","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0430","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00432-019-03118-4","article-title":"Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes","volume":"146","author":"Kiweler","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0435","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1158\/0008-5472.CAN-08-2546","article-title":"Histone deacetylase inhibitor sodium butyrate enhances the cell killing effect of psoralen plus UVA by attenuating nucleotide excision repair","volume":"69","author":"Toyooka","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0440","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0445","doi-asserted-by":"crossref","first-page":"583","DOI":"10.18388\/abp.2002_3768","article-title":"Recognition and repair of DNA-cisplatin adducts","volume":"49","author":"Wozniak","year":"2002","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.bbamcr.2025.120018_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51","volume":"8","author":"Xie","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbamcr.2025.120018_bb0455","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biopha.2017.09.078","article-title":"Curcumin sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous recombination","volume":"97","author":"Zhao","year":"2018","journal-title":"Biomed. Pharmacother."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488925001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488925001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T07:31:15Z","timestamp":1754465475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488925001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":91,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0167488925001235"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2025.120018","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome acquired cisplatin resistance of tumor cells","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2025.120018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120018"}}